113 filings
Page 2 of 6
8-K
uv1p6fqkg1rz07
15 May 23
Novan Reports First Quarter 2023 Financial Results and Provides
6:50am
8-K
lxcas5gh86p21e
7 Apr 23
Departure of Directors or Certain Officers
5:26pm
8-K
nij5wkrguyc 3htfa9x
30 Mar 23
Novan Reports Full Year 2022 Financial Results and Provides
6:36am
8-K
wh0xcf0ip8tb4bij
16 Mar 23
Entry into a Material Definitive Agreement
4:21pm
8-K
dx4 mfa6tprb5hx2s4
13 Mar 23
Other Events
6:07am
8-K
j8uf myaclsv7q1
7 Mar 23
Results of Operations and Financial Condition
8:06am
8-K
y08kih
6 Jan 23
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
8:05am
8-K
9765wa n0x
21 Dec 22
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADEĀ® in Japan
8:05am
8-K
supx3zt
6 Dec 22
Entry into a Material Definitive Agreement
6:30am
8-K
ppzcz8wn13vdttpjq
14 Nov 22
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:05am
8-K
w6zmgt38s rjs
11 Aug 22
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:35am
8-K
r90x0eusx39qpi2 0o
19 Jul 22
Termination of a Material Definitive Agreement
8:20am
8-K
2e7tc
10 Jun 22
Entry into a Material Definitive Agreement
4:11pm
8-K
aayvil0 2mqvim2cu2
8 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
e2ut08ckreq1hv6f
20 May 22
Other Events
5:16pm
8-K
gnr9fo
16 May 22
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
6:34am
8-K
0avrwlt
11 Mar 22
Entry into a Material Definitive Agreement
7:04am
8-K
h2glwyta2qki3 sn
11 Mar 22
Entry into a Material Definitive Agreement
6:43am
8-K
f9od7rl7zfv un0
30 Nov 21
Entry into a Material Definitive Agreement
4:06pm
8-K
7mwcqt
10 Nov 21
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
12:00am